Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Mohrherr, J; Haber, M; Breitenecker, K; Aigner, P; Moritsch, S; Voronin, V; Eferl, R; Moriggl, R; Stoiber, D; Győrffy, B; Brcic, L; László, V; Döme, B; Moldvay, J; Dezső, K; Bilban, M; Popper, H; Moll, HP; Casanova, E.
JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
Int J Cancer. 2019; 145(12):3376-3388 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Brcic Luka
Popper Helmuth
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 5
| | | | |
Abstract:
Oncogenic K-RAS has been difficult to target and currently there is no K-RAS-based targeted therapy available for patients suffering from K-RAS-driven lung adenocarcinoma (AC). Alternatively, targeting K-RAS-downstream effectors, K-RAS-cooperating signaling pathways or cancer hallmarks, such as tumor-promoting inflammation, has been shown to be a promising therapeutic strategy. Since the JAK-STAT pathway is considered to be a central player in inflammation-mediated tumorigenesis, we investigated here the implication of JAK-STAT signaling and the therapeutic potential of JAK1/2 inhibition in K-RAS-driven lung AC. Our data showed that JAK1 and JAK2 are activated in human lung AC and that increased activation of JAK-STAT signaling correlated with disease progression and K-RAS activity in human lung AC. Accordingly, administration of the JAK1/2 selective tyrosine kinase inhibitor ruxolitinib reduced proliferation of tumor cells and effectively reduced tumor progression in immunodeficient and immunocompetent mouse models of K-RAS-driven lung AC. Notably, JAK1/2 inhibition led to the establishment of an antitumorigenic tumor microenvironment, characterized by decreased levels of tumor-promoting chemokines and cytokines and reduced numbers of infiltrating myeloid derived suppressor cells, thereby impairing tumor growth. Taken together, we identified JAK1/2 inhibition as promising therapy for K-RAS-driven lung AC. © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

Find related publications in this database (Keywords)
non-small cell lung cancer
lung adenocarcinoma (AC)
Kirsten rat sarcoma viral proto-oncogene (K-RAS)
Janus kinase (JAK)
ruxolitinib
cell-line derived xenografts
genetically engineered mouse models
tumor microenvironment (TME)
tumor promoting inflammation
© Med Uni Graz Impressum